The information on this website is intended to provide scientific information about Alkermes products and areas of therapeutic interest. Information may include data on investigational uses of approved or unapproved drugs for which safety and effectiveness have not been established. There is no guarantee that such uses will receive health authority approval and Alkermes does not recommend or suggest use of its medicines in a manner inconsistent with approved labeling.
This section includes selected Alkermes abstracts, posters or oral presentations, which have been accepted for congress presentations in the last 2 years. The content contained in this section is subject to congress copyright permissions.
Leslie Citrome, MD, MPH,1 Christoph U. Correll, MD,2-6 Roger S. McIntyre, MD,7 Mark S. Todtenkopf, PhD,8 Christina Arevalo, MS,8 James A. McGrory, PhD,8 David McDonnell, MD9
1New York Medical College, Valhalla, NY, USA; 2Zucker Hillside Hospital, Department of Psychiatry, Glen Oaks, NY, USA; 3Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Department of Psychiatry and Molecular Medicine Hempstead, Hempstead, NY, USA; 4The Feinstein Institute for Medical Research, Center for Psychiatric Neuroscience, Northwell Health, New Hyde Park, NY, USA; 5Charité Universitätsmedizin, Department of Child and Adolescent Psychiatry, Berlin, Germany; 6German Center for Mental Health (DZPG), partner site Berlin, Berlin, Germany; 7University of Toronto, Department of Psychiatry and Pharmacology and Toxicology, Toronto, ON, Canada; 8Alkermes, Inc., Waltham, MA, USA; 9Alkermes Pharma Ireland Ltd., Dublin, Ireland
